RxDoctor Payments Data

Renato Saltz

Salt Lake City, UTNPI 1518083195

Payments from drug & device makers

What this record shows

This record is dominated by grants: $262,250 of the $301,054 with a category attached, or 87.1%. AbbVie accounts for 97.6% of it on its own, with 9 other manufacturers making up the rest.

$301,054in general payments, 2019–2025

Across 165 payments — averaging $1824.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$294K
  • Galderma Laboratories, L.p.$6K
  • Integra Lifesciences Corporation$368
  • Merz North America, Inc.$241
  • Revance Therapeutics, Inc.$184
  • Mentor Worldwide LLC$167
  • plus $222 from 4 others

What the payments were for

  • Consulting fees$26,1849%
  • Speaking & faculty fees$7,7933%
  • Grants$262,25087%
  • Food & beverage$2,7731%
  • Gifts$2,0541%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →